Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

NCT05119569 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05119569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05119569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2022
Completion date
June 30, 2027
Enrollment
109 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis